Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes : Episode 3
Overview of FLAURA and MARIPOSA-2 Clinical Trials
Dr. Kim reviews key clinical evidence from the FLAURA trial for osimertinib as a first-line therapy in EGFR+ metastatic NSCLC and discusses the MARIPOSA 2 trial supporting amivantamab with chemotherapy as the preferred second-line option.
EP: 1.Robert’s Journey With EGFR+ Metastatic NSCLC
EP: 2.The Impact of Molecular Testing on Treatment Choices for NSCLC
Now Viewing
EP: 3.Overview of FLAURA and MARIPOSA-2 Clinical Trials
EP: 4.Clinical Experience of Amivantamab in EGFR+ NSCLC Patients
EP: 5.Factors in Selecting Treatment Options for EGFR+ NSCLC
EP: 6.Evaluating Treatment Options of EGFR Inhibitors
EP: 7.Considerations for Second-Line Treatment Decisions in EGFR+ NSCLC: Sequencing Strategies and First-Line Choices
EP: 8.Jason’s Journey with ALK+ Metatstatic NSCLC
EP: 9.Barriers and Challenges in Biomarker Testing for ALK+ NSCLC
EP: 10.Overview of Efficacy of Lorlatinib in the Treatment of ALK+ NSCLC
EP: 11.Overview of Current Treatment Landscape of ALK Inhibitors
EP: 12.Clinical Experience of Lorlatinib ALK+ NSCLC Patients
EP: 13.Patient Factors Considered when Choosing Treatment Selection
EP: 14.Treatment Strategies in Disease Progression in ALK+ NSCLC
EP: 15.Evaluating ALK Inhibitors in Treatment Sequencing and Testing
EP: 16.Future Therapies for ALK+ Metastatic NSCLC
Video content above is prompted by the following:
- Provide an overview of the clinical evidence from the FLAURA trial supporting osimertinib as a first-line treatment for EGFR+ metastatic NSCLC.
- Review the evidence from the MARIPOSA-2 trial supporting amivantamab plus chemotherapy as the best second-line option for this patient.
Recent Videos
